Beam has a couple of therapies targeting rarer diseases than SCD, like alpha-1 antitrypsin deficiency (AATD) and glycogen storage disease type 1a (GSD1A). In my view, these markets have lower ...

May 29, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq ... to correct the disease-causing mutation in patients with alpha-1 antitrypsin deficiency (AATD). AATD is an inherited genetic ...

May 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq ... to correct the disease-causing mutation in patients with alpha-1 antitrypsin deficiency (AATD). AATD is an inherited genetic ...

First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease ... Following Positive Initial Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency, Company Initiated Dosing ...

has granted orphan drug designation to BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation of a guide RNA and an mRNA encoding a base editor designed to correct the disease-causing ...

designation to BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation of a guide RNA and an mRNA encoding a base editor designed to correct the disease-causing mutation in patients with ...

he said. The culprit was a balloon. “The cause of the alarm was due to a balloon that interfered with the connection of a beam detector,” Chris Williams, a Davis School District spokesman ...

The Russell 2000® Alpha Tilts Fund (the “Fund”) seeks investment results that approximate the capitalization weighted total rate of return of the Benchmark listed herein. The portfolio is ...